Published in Br J Pharmacol on April 01, 1995
Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology (Berl) (2004) 0.84
Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev (1993) 4.69
A potent nonpeptide antagonist of the substance P (NK1) receptor. Science (1991) 4.06
Neurotransmitter functions of mammalian tachykinins. Physiol Rev (1993) 2.59
Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A (1991) 2.30
Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol (1993) 1.92
Mammalian tachykinin receptors. Annu Rev Neurosci (1991) 1.78
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.60
Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J (1990) 1.51
Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.46
Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. J Neurosci (1989) 1.27
Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther (1993) 1.26
Angiotensin II actions in paraventricular nucleus: functional evidence for neurotransmitter role in efferents originating in subfornical organ. Brain Res (1992) 1.26
Cardiovascular response to stress. Physiol Rev (1991) 1.23
Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. J Biol Chem (1992) 1.17
Neurokinin A (NK2) receptor revisited with SR 48968, a potent non-peptide antagonist. Biochem Biophys Res Commun (1992) 1.17
Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul Pept (1993) 1.04
Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev (1994) 1.03
Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Res Brain Res Rev (1993) 0.99
Distribution of neurons expressing neurokinin B in the rat brain: immunohistochemistry and in situ hybridization. J Comp Neurol (1992) 0.97
[3H]neurokinin B and 125I-Bolton Hunter eledoisin label identical tachykinin binding sites in the rat brain. J Neurochem (1987) 0.97
Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull (1993) 0.97
Intracerebroventricular administration of AT1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J Neurochem (1994) 0.96
Antagonists for the neurokinin NK-3 receptor evaluated in selective receptor systems. Regul Pept (1990) 0.96
The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. Br J Pharmacol (1988) 0.95
Immunohistochemical mapping of angiotensin AT1 receptors in the brain. Regul Pept (1993) 0.93
The selective NK3 receptor agonist senktide excites a subpopulation of dopamine-sensitive neurones in the rat substantia nigra pars compacta in vitro. Br J Pharmacol (1992) 0.92
Non-peptide angiotensin II receptor antagonists discriminate subtypes of 125I-angiotensin II binding sites in the rat brain. Eur J Pharmacol (1990) 0.92
Quantitative autoradiography reveals different angiotensin II receptor subtypes in selected rat brain nuclei. J Neurochem (1991) 0.92
Behavioural effects of tachykinins and related peptides. Brain Res (1986) 0.92
Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br J Pharmacol (1994) 0.92
Agonists selective for tachykinin NK1 and NK3 receptors excite subpopulations of neurons in the rat medial habenula nucleus in vitro. Eur J Pharmacol (1993) 0.91
Nonpeptide antagonists herald new era in tachykinin research. Trends Pharmacol Sci (1992) 0.91
Evidence for the presence of angiotensin II-type 1 receptors in brain. Brain Res Bull (1990) 0.90
Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin. Eur J Pharmacol (1981) 0.90
Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors. Proc Natl Acad Sci U S A (1994) 0.88
Role of central tachykinin peptides in cardiovascular regulation in rats. Brain Res (1990) 0.88
Identification of the central tachykinin receptor subclass involved in substance P-induced cardiovascular and behavioral responses in conscious rats. Eur J Pharmacol (1992) 0.87
Differential effects of central angiotensin II and substance P on sympathetic nerve activity in conscious rats. Implications for cardiovascular adaptation to behavioral responses. Circ Res (1985) 0.86
Effects of a non-peptide angiotensin receptor antagonist on drinking and blood pressure responses to centrally administered angiotensins in the rat. Brain Res (1992) 0.85
Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors. Proc Natl Acad Sci U S A (1993) 0.85
Access of peripherally administered DuP 753 to rat brain angiotensin II receptors. Br J Pharmacol (1991) 0.84
The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev (1992) 0.83
Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats. Brain Res Dev Brain Res (1993) 0.82
Functional role of brain AT1 and AT2 receptors in the central angiotensin II pressor response. Brain Res (1993) 0.82
Central pressor actions of neurokinin B: increases in neurokinin B contents in discrete nuclei in spontaneously hypertensive rats. Brain Res (1989) 0.82
[125I]-Bolton-Hunter scyliorhinin II: a novel, selective radioligand for the tachykinin NK3 receptor in rat brain. Peptides (1990) 0.81
The neurogenic origin of hypertension in SHR may be mediated by angiotensin II through a receptor different from AT1 and AT2. Regul Pept (1993) 0.81
Quantitative autoradiographic analysis of the distribution of binding sites for [125I]Bolton Hunter derivatives of eledoisin and substance P in the rat brain. Neuroscience (1986) 0.81
Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens Suppl (1993) 0.81
The renin-angiotensin system in the brain: an update 1993. Regul Pept (1993) 0.81
Conserved HisVI-17 of the NK-1 receptor is involved in binding of non-peptide antagonists but not substance P. FEBS Lett (1993) 0.81
Central pressor actions of tachykinin NK-3 receptor in the paraventricular nucleus of the rat hypothalamus. Brain Res (1992) 0.79
Selective agonists at NK3 tachykinin receptors inhibit alcohol intake in Sardinian alcohol-preferring rats. Brain Res Bull (1994) 0.79
Tachykinin receptor subtypes involved in the central effects of tachykinins on water and salt intake. Brain Res Bull (1991) 0.79
Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat. Neurosci Lett (1993) 0.79
Eledoisin, substance P and related peptides: intracranial dipsogens in the pigeon and antidipsogens in the rat. Brain Res (1978) 0.79
Central organization of sympathetic cardiovascular response to pain. Annu Rev Physiol (1988) 0.79
Functional mapping of the ligand binding sites of G-protein coupled receptors. Med Res Rev (1994) 0.78
Effects of angiotensin II AT1- or AT2-receptor antagonists on drinking evoked by angiotensin II or water deprivation in rats. Brain Res (1994) 0.78
Neurohormonal control of salt intake in the rat. Brain Res Bull (1992) 0.78
Cardiovascular and dipsogenic effects of angiotensin II administered i.c.v. in Long-Evans and Brattleboro rats. Brain Res (1988) 0.78
The effect of the putative AT2 agonist, p-aminophenylalanine6 angiotensin II, on thirst and sodium appetite in rats. Exp Physiol (1993) 0.77
Role of NK-2 receptors in the antidipsogenic activity of neurokinins in the mouse. Gen Pharmacol (1992) 0.76
The reduction in alcohol drinking by peripherally injected angiotensin II is selectively mediated by the AT1 receptor subtype. Pharmacol Biochem Behav (1994) 0.76
Non-peptide angiotensin receptor antagonists bind to tachykinin NK3 receptors of rat and guinea pig brain. Eur J Pharmacol (1994) 0.76
Effect of a nonpeptide angiotensin II receptor antagonist, DuP 753, on angiotensin-related water intake in rats. Brain Res Bull (1991) 0.76
Intravenous losartan inhibits the increase in plasma luteinizing hormone and water intake produced by intraventricular angiotensin II. Proc Soc Exp Biol Med (1994) 0.76
Inhibitory effect of the nonpeptide angiotensin II receptor antagonist losartan and its active metabolite, E-3174, on cAMP phosphodiesterase: additional action of the antagonists. Biochem Pharmacol (1994) 0.76
Inhibitory role on gastric secretion of a central NK-3 tachykinin receptor agonist, senktide. Peptides (1992) 0.76
Mapping of brain sites sensitive to the antidipsogenic effect of tachykinins. Peptides (1988) 0.75
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci (1988) 1.83
Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J (1990) 1.51
Studies on the trigeminal antidromic vasodilatation and plasma extravasation in the rat. J Physiol (1984) 1.13
Peptides and the human colon: an in vitro pharmacological study. Can J Physiol Pharmacol (1981) 1.05
Bradykinin analogue blocks bradykinin-induced inhibition of a spinal nociceptive reflex in the rat. Eur J Pharmacol (1987) 1.03
Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema. Peptides (1996) 1.02
Kinin B1 receptor expression and function on human brain endothelial cells. J Neuropathol Exp Neurol (2000) 0.96
Development of digoxigenin-labeled peptide: application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides (1994) 0.95
Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors. Br J Pharmacol (2008) 0.95
LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther (1997) 0.95
Hepoxilin A3 increases vascular permeability in the rat skin. Eicosanoids (1991) 0.94
Serum interspecies differences in metabolic pathways of bradykinin and [des-Arg9]BK: influence of enalaprilat. Am J Physiol (1996) 0.93
Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs. Br J Pharmacol (1993) 0.93
Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat. Br J Pharmacol (1992) 0.92
Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists. Br J Pharmacol (1994) 0.92
Intrathecal bradykinin acts presynaptically on spinal noradrenergic terminals to produce antinociception in the rat. Eur J Pharmacol (1989) 0.92
Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides (2007) 0.91
Calcium and vitamin D use among adults in periodontal disease maintenance programmes. Br Dent J (2009) 0.90
Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br J Pharmacol (2000) 0.89
Plasma protein extravasation induced by mammalian tachykinins in rat skin: influence of anaesthetic agents and an acetylcholine antagonist. Br J Pharmacol (1987) 0.89
Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum (1997) 0.87
Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology (1999) 0.87
Pharmacological effects of peptides on tracheal smooth muscle. Pharmacology (1982) 0.87
Characterization and immunocytochemical application of monoclonal antibodies against enkephalins. J Histochem Cytochem (1984) 0.87
Mini review: smooth muscle pharmacology of substance P. Pharmacology (1982) 0.86
Role of kinin B1 and B2 receptors in a rat model of neuropathic pain. Int Immunopharmacol (2007) 0.85
Spinal action of neurokinins producing cardiovascular responses in the conscious freely moving rat: evidence for a NK-1 receptor mechanism. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.85
Hepoxilins sensitize blood vessels to noradrenaline--stereospecificity of action. Br J Pharmacol (1992) 0.85
The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol (2007) 0.85
Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat. Br J Pharmacol (1997) 0.84
Comparison of renal osteodystrophy in patients dialyzed with deionized and non-deionized water. Trans Am Soc Artif Intern Organs (1972) 0.84
Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des (2005) 0.84
Sympathoadrenal mechanisms underlying cardiovascular responses to intrathecal substance P in conscious rats. J Cardiovasc Pharmacol (1990) 0.84
Astroglial distribution of neurokinin-2 receptor immunoreactivity in the rat spinal cord. Neuroscience (1998) 0.84
Hepoxilin A3 (HxA3) is formed by the rat aorta and is metabolized into HxA3-C, a glutathione conjugate. Biochim Biophys Acta (1991) 0.83
Blockade of kinin B(1) receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance. Diabetes Obes Metab (2011) 0.83
Modulatory effect of bradykinin on noradrenaline release in isolated atria from normal and B2 knockout transgenic mice. Eur J Pharmacol (1998) 0.83
Prostacyclin release induced by neurokinins in cultured human endothelial cells. Can J Physiol Pharmacol (1989) 0.83
Cardiovascular responses induced by intrathecal substance P in the conscious freely moving rat. J Cardiovasc Pharmacol (1989) 0.83
In vivo B2-receptor-mediated negative chronotropic effect of bradykinin in canine sinus node. Am J Physiol (1993) 0.83
Accumulation of lymph around the transplanted kidney (lymphocele) mimicking renal allograft rejection. J Urol (1974) 0.83
Activation of Mas oncogene-related gene (Mrg) C receptors enhances morphine-induced analgesia through modulation of coupling of μ-opioid receptor to Gi-protein in rat spinal dorsal horn. Neuroscience (2013) 0.83
Localization of bradykinin-like immunoreactivity in the rat spinal cord: effects of capsaicin, melittin, dorsal rhizotomy and peripheral axotomy. Neuroscience (1997) 0.82
Use of non-peptide tachykinin receptor antagonists to substantiate the involvement of NK1 and NK2 receptors in a spinal nociceptive reflex in the rat. Eur J Pharmacol (1993) 0.82
Cardiovascular effects of intrathecally administered bradykinin in the rat: characterization of receptors with antagonists. Br J Pharmacol (1993) 0.82
Modulation of cardiac activity by tachykinins in the rat substantia nigra. Br J Pharmacol (2001) 0.82
Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension. Neuropeptides (2010) 0.82
Cardiovascular responses elicited by intrathecal kinins in the conscious rat. Eur J Pharmacol (1992) 0.82
Inactivation of substance P and its C-terminal fragments in rat plasma and its inhibition by Captopril. Can J Physiol Pharmacol (1981) 0.81
Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol (1999) 0.81
Mechanisms of kinin B1-receptor-induced hypotension in the anesthetized dog. J Cardiovasc Pharmacol (1996) 0.81
Cardiovascular and sympathoadrenal responses to intrathecal injection of neuropeptide K in the conscious rat. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.81
Neurokinin receptors in the guinea pig ileum. Pharmacology (1996) 0.81
Inhibitory action of (+/-)CP-96,345 on the cardiovascular responses to intrathecal substance P and neuropeptide K in the conscious freely moving rat. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.80
Hemodynamic and renal involvement of B1 and B2 kinin receptors during the acute phase of endotoxin shock in mice. Int Immunopharmacol (2007) 0.80
Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria. Br J Pharmacol (1995) 0.80
Short-term desensitization of the angiotensin II receptor of bovine adrenal glomerulosa cells corresponds to a shift from a high to a low affinity state. Endocrinology (1994) 0.80
Characterization of the effects produced by neurokinins and three agonists selective for neurokinin receptor subtypes in a spinal nociceptive reflex of the rat. Life Sci (1988) 0.80
Characterization of the peripheral action of neuropeptide K on the rat cardiovascular system. Eur J Pharmacol (1992) 0.80
The dog common carotid artery: a sensitive bioassay for studying vasodilator effects of substance P and of kinins. Can J Physiol Pharmacol (1980) 0.80
A role for B1 and B2 kinin receptors in the modulation of T-kininogen during the acute phase response of inflammation. Peptides (1996) 0.80
Autoradiographic localization of [125I-Tyr8]-bradykinin receptor binding sites in the guinea pig spinal cord. Synapse (1993) 0.80
Two NK-3 receptor subtypes: demonstration by biological and binding assays. Neuropeptides (1994) 0.79
Quantitative autoradiographic localization of [125I-Tyr8]bradykinin receptor binding sites in the rat spinal cord: effects of neonatal capsaicin, noradrenergic deafferentation, dorsal rhizotomy and peripheral axotomy. Neuroscience (1995) 0.79
Structure-activity studies on the C-terminal amide of substance P. J Med Chem (1982) 0.79
The selection of needs indicators for regional resource allocation in the fields of health and social services in Québec. Soc Sci Med (1996) 0.79
Trigeminal antidromic vasodilatation and plasma extravasation in the rat: effects of sensory, autonomic and motor denervation. Brain Res (1985) 0.79
Spinal cord serotonin receptors in cardiovascular regulation and potentiation of the pressor response to intrathecal substance P after serotonin depletion. Can J Physiol Pharmacol (1993) 0.79
Cardiovascular and behavioural effects of centrally administered neuropeptide K in the rat: receptor characterization. Br J Pharmacol (1994) 0.79
Effect of uncoupling agents on AT1 receptor affinity for antagonist analogs of angiotensin II. Receptors Channels (1998) 0.79
Neurokinin A-induced contraction of guinea-pig isolated trachea: potentiation by hepoxilins. Br J Pharmacol (1992) 0.78
Immunoelectron microscopic localization of NK-3 receptor in the rat spinal cord. Neuroreport (1997) 0.78
Apolipoprotein E polymorphism in a French Canadian population of northeastern Quebec: allele frequencies and effects on blood lipid and lipoprotein levels. Hum Biol (1996) 0.78
Peripheral effects of three novel non-peptide tachykinin NK1 receptor antagonists in the anaesthetized rat. Eur J Pharmacol (1996) 0.78
The effect of host immunity on hepatitis B antigen (HBAg) infection in hemodialysis patiets. Trans Am Soc Artif Intern Organs (1975) 0.78
Vascular reactivity to angiotensin and noradrenaline following nephrectomy in rats. Clin Exp Hypertens (1980) 0.78
Studies on the vascular permeability induced by intrathecal substance P and bradykinin in the rat. Eur J Pharmacol (1990) 0.78
Reflex adrenal medullary secretion during coronary occlusion mediated by cardiac receptors with afferent vagal fibres in the rat. Pflugers Arch (1997) 0.77
Stimulation of the angiotensin II type I receptor on bovine adrenal glomerulosa cells activates a temperature-sensitive internalization-recycling pathway. Mol Cell Endocrinol (1997) 0.77
Characterization of the cardiovascular and behavioral effects of centrally administered neuropeptide K in the conscious rat. Regul Pept (1993) 0.77
Characterization of novel platelet and endothelial cell target antigens in a family with genetic susceptibility to autoimmunity. Am J Hematol (1991) 0.77
Increased pulmonary vascular permeability and oedema induced by intrathecally injected endothelins in rat. Eur J Pharmacol (1998) 0.77
Vascular reactivity to angiotensin and noradrenaline in rats maintained on a sodium free diet or made hypertensive with desoxycorticosterone acetate and salt (DOCA/salt). Clin Exp Hypertens (1980) 0.77
Neuropeptide K potently stimulates the hydrolysis of phosphatidylinositol in the rat spinal cord. Neurosci Lett (1993) 0.77
Renal effects of intracerebroventricularly injected tachykinins in the conscious saline-loaded rat: receptor characterization. Br J Pharmacol (1997) 0.77
Choline acetyltransferase activity in the rat trigeminal system. J Neurochem (1985) 0.77
Role of capsaicin-sensitive sensory nerves in mediation of the cardiovascular effects of the essential oil of croton zehntneri leaves in anaesthetized rats. Clin Exp Pharmacol Physiol (2006) 0.76
Spinal actions of substance P analogues on cardiovascular responses in the rat: a structure-activity analysis. Can J Physiol Pharmacol (1987) 0.76
Effect of angiotensin II on a spinal nociceptive reflex in the rat: receptor and mechanism of action. Life Sci (1997) 0.76
Trigeminal antidromic vasodilatation and plasma extravasation in the rat: effects of acetylcholine antagonists and cholinesterase inhibitors. Br J Pharmacol (1985) 0.76
Regulation of cardiovascular sympathetic neurons by substance P and gamma-aminobutyric acid in the rat spinal cord. Eur J Pharmacol (1991) 0.76
Synthesis of peptides by the solid-phase method. 7. Substance P and analogues. J Med Chem (1982) 0.76
Antioxidant/oxidant status and cardiac function in bradykinin B(1)- and B(2)-receptor null mice. Physiol Res (2013) 0.76
Studies on the cardiovascular effects produced by the spinal action of two substance P analogues in the rat: evidence for a central catecholaminergic mechanism. Eur J Pharmacol (1987) 0.76
Capillary permeability induced by intravenous neurokinins. Receptor characterization and mechanism of action. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.76
Tetrapeptide tachykinin antagonists: synthesis and modulation of the physicochemical and pharmacological properties of a new series of partially cyclic analogs. J Med Chem (1993) 0.76
Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists. Br J Pharmacol (1996) 0.75
Effects of substance P analogues in the rat tail-flick test. Eur J Pharmacol (1987) 0.75